INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Pricing of Public Offering of Common Stock
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 25, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price
View HTML
Toggle Summary NantKwest Announces Proposed Public Offering of Common Stock
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 24, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public
View HTML
Toggle Summary NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
 NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments NantKwest’s PD-L1 t-haNK cells, haNK cells engineered
View HTML
Toggle Summary ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for potential long-lasting humoral and
View HTML
Toggle Summary NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
EL SEGUNDO, Calif. ,--(BUSINESS WIRE)--May 26, 2020-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc. , today announced that Patrick Soon-Shiong , M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET .
View HTML
Toggle Summary NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm Trial anticipated to initiate in Los Angeles area hospitals in Q2 Proprietary automated “GMP-in-a-Box”, an in-house
View HTML
Toggle Summary NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer patient treated with PD-L1 t-haNK
View HTML
Toggle Summary NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Apr. 29, 2020-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc. , today announced that Patrick Soon-Shiong , M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at
View HTML
Toggle Summary NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to Protect Against SARS-CoV-2 Infection:
View HTML
Toggle Summary NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif. --(BUSINESS WIRE)-- NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.